Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Noteworthy Monday Option Activity: CORT, CWH, HELE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Corcept Therapeutics Inc , where a total of 6,472 contracts have traded so far, representing...

CORT : 15.35 (+2.68%)
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference...

CORT : 15.35 (+2.68%)
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing's Syndrome of Adrenal Origin

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 15.35 (+2.68%)
Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 15.35 (+2.68%)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 2.04 (+0.99%)
ONC.TO : 2.67 (-3.26%)
PFE : 38.35 (-0.34%)
LLY : 152.84 (+1.70%)
NVTA : 32.07 (+9.83%)
CLVS : 6.14 (+6.04%)
CORT : 15.35 (+2.68%)
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

MRK : 82.54 (+2.87%)
CORT : 15.35 (+2.68%)
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CORT : 15.35 (+2.68%)
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Is (CORT) Outperforming Other Medical Stocks This Year?

CORT : 15.35 (+2.68%)
Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 15.35 (+2.68%)
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

MRK : 82.54 (+2.87%)
BMY : 59.10 (+0.75%)
CORT : 15.35 (+2.68%)
ATXI : 10.18 (+0.49%)
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CORT : 15.35 (+2.68%)
Corcept: 1Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Monday reported first-quarter net income of $30.1 million.

CORT : 15.35 (+2.68%)
Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 15.35 (+2.68%)
Cushing's Syndrome Pipeline Insight, 2020 Featuring Novartis Pharmaceuticals, Cortendo AB, Corcept Therapeutics and HRA Pharma - ResearchAndMarkets.com

The "Cushing's Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

CORT : 15.35 (+2.68%)
NVS : 83.65 (+1.84%)
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 4, 2020. The company will also host a conference call...

CORT : 15.35 (+2.68%)
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

CORT : 15.35 (+2.68%)
5 Growth ETFs & Stocks Set to Flourish in Spring

Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.

KGC : 9.28 (-0.96%)
FLWS : 29.52 (+4.50%)
TREE : 360.50 (+4.10%)
CORT : 15.35 (+2.68%)
NPTN : 9.83 (+7.90%)
IUSG : 77.75 (+1.12%)
VUG : 219.77 (+1.10%)
MGK : 178.02 (+1.13%)
SPYG : 48.57 (+1.00%)
SCHG : 110.64 (+1.14%)
RedHill (RDHL) Soars: Stock Adds 9.2% in Session

RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

CORT : 15.35 (+2.68%)
RDHL : 7.80 (-1.64%)
Corcept Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.

CORT : 15.35 (+2.68%)
Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock

Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CORT : 15.35 (+2.68%)

Van Meerten Stock Picks

Ebay - Pick of the Day
Today Ebay (EBAY) is a Volume Leader on Barchart: 100% technical buy signals Trend Spotter buy signal Above its 20, 50 and 100 Day moving averages 16 new highs and up 26.
EBAY +1.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar